Based on these positive findings, we are enthusiastic about further investigating VEGF signaling in TSC & LAM pathogenesis and additional TSC preclinical studies evaluating other VEGF pathway inhibitors as well as different schedules and dosing of the combination of VEGF inhibitors plus rapamycin. Here, VEGFA is linked to tuberous sclerosis.